## WHAT IS CLAIMED IS:

8 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,979 9 SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,597; SEQ ID NO:10,974; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,486 - 10,536; SEQ ID NO:10,537 - 10,580; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,970; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	1	1. An isolated polynucleotide comprising a sequence selected from the			
NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (b) complements of any of the sequences provided in SEQ ID NOs:10,486  - 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597  SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NO:10,486 – 10,536; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,972; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.	2	group consisting of:			
NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (b) complements of any of the sequences provided in SEQ ID NOs:10,486  - 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597  SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NO:10,486 – 10,536; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,972; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.	3	(a) the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID			
NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (b) complements of any of the sequences provided in SEQ ID NOs:10,486  10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597  SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,973; and SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,975; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
(b) complements of any of the sequences provided in SEQ ID NOs:10,486 complements of any of the sequences provided in SEQ ID NOs:10,486 logical Provided in SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597 SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,486 – 10,536; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,973; and SEQ ID NO:10,974; SEQ ID NO:10,974; SEQ ID NO:10,974; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
8 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,979 9 SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,597; SEQ ID NO:10,974; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,486 - 10,536; SEQ ID NO:10,537 - 10,580; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,597; SEQ ID NO:10,970; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.	7	(b) complements of any of the sequences provided in SEQ ID NOs:10,486			
SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.	8				
NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;  (c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID  NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ  ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID  NOs:10,486 – 10,536; SEQ ID NO:10,537 – 10,580; SEQ ID NO:10,973; and SEQ ID  NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID  NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID  NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  3 (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1  operably linked to an expression control sequence.					
NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	了 11				
NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	12				
ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	-13				
NO:10,974; and  (d) degenerate variants of any one of the sequences provided in SEQ ID  NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ II  NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID  NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	14				
degenerate variants of any one of the sequences provided in SEQ ID  NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID  NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID  NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  3 (a) sequences encoded by a polynucleotide of claim 1; and  4 (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3 An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ II NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: 3 (a) sequences encoded by a polynucleotide of claim 1; and 4 (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  3 (a) sequences encoded by a polynucleotide of claim 1; and  4 (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	7. 7.1.7				
NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.  An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	18				
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	19				
from the group consisting of:  (a) sequences encoded by a polynucleotide of claim 1; and  (b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.					
3 (a) sequences encoded by a polynucleotide of claim 1; and 4 (b) sequences having at least 90% identity to a sequence encoded by a 5 polynucleotide of claim 1. 1 3. An expression vector comprising a polynucleotide of claim 1 2 operably linked to an expression control sequence.	1	2 An isolated polypeptide comprising an amino acid sequence selected			
(b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	2	from the group consisting of:			
polynucleotide of claim 1.  3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	3	(a) sequences encoded by a polynucleotide of claim 1; and			
3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.	4	(b) sequences having at least 90% identity to a sequence encoded by a			
operably linked to an expression control sequence.	5	polynucleotide of claim 1.			
	1	3. An expression vector comprising a polynucleotide of claim 1			
1 A host cell transformed or transfected with an expression vector	2	operably linked to an expression control sequence.			
A HOSE CON ELEMISION OF MEMBERS AND AND ADDRESS OF A CONTROL OF MEMBERS AND ADDRESS OF A CONTROL OF A CONTR	. 1	4. A host cell transformed or transfected with an expression vector			
2 according to claim 3.					

1		5.	An isolated antibody, or antigen-binding fragment thereof, that
2	specifically b	oinds to	a polypeptide of claim 2.
1		6.	A method for detecting the presence of a cancer in a patient,
2	comprising the		
3	comprising the	(a)	obtaining a biological sample from the patient;
4		(b)	contacting the biological sample with a binding agent that binds to a
		(0)	
5		(-)	polypeptide of claim 2;
6		(c)	detecting in the sample an amount of polypeptide that binds to the
7			binding agent; and
8		(d)	comparing the amount of polypeptide to a predetermined cut-off value
<u> </u>			and therefrom determining the presence of a cancer in the patient.
달 6 1		7.	A fusion protein comprising at least one polypeptide according to
	claim 2.	,.	71 fusion protein comprising at least one polypeptide according to
	Claim 2.		
		8.	The fusion protein of claim 7, further comprising Ra12.
æ			
<b>1</b>		9.	The fusion protein of claim 7, further comprising a His tag.
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		10.	An oligonucleotide that hybridizes to the polynucleotides of claim 1.
			ongoine of the region of the projection of the region
TJ 1		11.	A method for stimulating and/or expanding T cells specific for a
2	tumo	r protei	n, comprising contacting T cells with at least one component selected
3	from the grou	ıp cons	isting of:
4		(a)	polypeptides according to claim 2;
5		(b)	polynucleotides according to claim 1; and
6		(c)	antigen-presenting cells that express a polypeptide according to claim
7			1, under conditions and for a time sufficient to permit the stimulation
8			and/or expansion of T cells.
1		12.	An isolated T cell population, comprising T cells prepared according to
2	the method o	f claim	11.
1		13.	A composition comprising a first component selected from the group
2	consisting of	physio	logically acceptable carriers and immunostimulants, and a second

3	component selected	from the group consisting of:		
4	(a)	polypeptides according to claim 2;		
5	(b)	polynucleotides according to claim 1;		
6	(c)	antibodies according to claim 5;		
7	(d)	fusion proteins according to claim 7;		
8	(e)	T cell populations according to claim 12; and		
9	(f) an	tigen presenting cells that express a polypeptide according to claim 2.		
1	14.	A method for stimulating an immune response in a patient, comprising		
2	administering to the	patient a composition of claim 13.		
1	15.	A method for the treatment of a cancer in a patient, comprising		
	administering to the	patient a composition of claim 13.		
<b>=</b> 1	16.	A method for determining the presence of a cancer in a patient,		
¥2	comprising the steps of:			
3	(a)	obtaining a biological sample from the patient;		
-	(b)	contacting the biological sample with an oligonucleotide according to		
<b>5</b>		claim 10;		
5 1 6 7 6 8	(c)	detecting in the sample an amount of a polynucleotide that hybridizes		
<b>4</b> 7		to the oligonucleotide; and		
Ţ 8	(d)	comparing the amount of polynucleotide that hybridizes to the		
9		oligonucleotide to a predetermined cut-off value, and therefrom		
10		determining the presence of the cancer in the patient.		
1	17.	A diagnostic kit comprising at least one oligonucleotide according to		
2	claim 10.			
1	18.	A diagnostic kit comprising at least one antibody according to claim 5		
2	and a detection reage	ent, wherein the detection reagent comprises a reporter group.		
1	19.	A method for inhibiting the development of a cancer in a patient,		
2	comprising the steps	of:		
-3	(a)	incubating CD4+ and/or CD8+ T cells isolated from a patient with at		
4		least one component selected from the group consisting of: (i)		
5		polyneptides according to claim 2: (ii) polynucleotides according to		

6			claim 1; and (iii) antigen presenting cells that express a polypeptide of
7			claim 2, such that T cell proliferate;
8		(b)	administering to the patient an effective amount of the proliferated T
9			cells, and thereby inhibiting the development of a cancer in the patient.
1		20.	An isolated polynucleotide comprising a sequence selected from the
2	group consist	ing of:	
3		(a)	sequence provided in SEQ ID NO:10,469 or SEQ ID NO:10,470;
4		(b)	complements of the sequence provided in SEQ ID NO:10,469 or SEQ
5	ID NO:10,470	0;	
6		(c)	sequences having at least 90% identity to SEQ ID NO:10,469 or SEQ
7	ID NO:10,470	0; and	
<b>4</b> 8		(d)	degenerate variants of SEQ ID NO:10,469 or SEQ ID NO:10,470.
<u>L</u> <u>L</u> 1		21.	An isolated polypeptide comprising an amino acid sequence provided
	in SEQ ID No	O:10,47	71 or SEQ ID NO:10,474.
1		22.	An isolated polynucleotide comprising a sequence selected from the
2	group consist	ing of:	
3		(a)	sequence provided in SEQ ID NO:10,480;
<b>4</b>		(b)	complements of the sequence provided in SEQ ID NO:10,480;
3 4 4 5		(c)	sequences having at least 90% identity to a sequence of SEQ ID
6	NO:10,480; a	nd	
7		(d)	degenerate variants of a sequence provided in SEQ ID NO:10,480.
1		23.	An isolated polypeptide comprising an amino acid sequence of SEQ ID
2	NO:10,481.		
1		24.	An isolated polypeptide comprising an amino acid sequence selected
2	from the grou	p consi	sting of:
3		(a)	sequences encoded by a polynucleotide of claim 20 or 22; and
4		(b)	sequences having at least 90% identity to a sequence encoded by a
5			polynucleotide of claim 20 or 22.

1	25.	An isolated polypeptide comprising an amino acid sequence selected
2	from the group consis	sting of:
3	(a)	sequences provided in any one of SEQ ID NOs:10,599 - 10,819; and
4	(b)	sequences provided in any one of SEQ ID NOs:10,820 – 10,842.
1	26.	An isolated polypeptide comprising an amino acid sequence selected
2	from the group consis	sting of:
3	(a)	sequences provided in any one of SEQ ID NOs:10,849 - 10,908; and
4	(b)	sequences provided in any one of SEQ ID NOs:10,909 - 10,968.